Since PPARγ is involved in carbohydrate metabolism, adipogenesis, and inflammation, PPARγ agonists have been widely used in the management of diabetes and oxidative stress-related diseases, and its antineoplastic effect against pancreatic cancer has been further confirmed in a series of studies [5]. The gene discussed is PPARG; the disease is familial pancreatic carcinoma.